



## **Presage Biosciences Granted Sixth U.S. Patent for CIVO™ Arrayed Microinjection Technology for Comparing Multiple Drugs in a Single Living Tumor**

Seattle – March 20, 2015 – Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,926,567, covering the company's CIVO™ arrayed microinjection platform.

This is Presage's sixth U.S. patent, providing intellectual property protection for its proprietary CIVO™ technology. The patent includes method claims covering the evaluation of drug response directly in a tumor.

"This patent builds upon Presage's already formidable intellectual property estate covering our CIVO technology that enables comparison of multiple drugs and combinations within a single living tumor, while still in a patient's body," said Nathan Caffo, President of Presage. "This technology makes it possible to incorporate patient drug response data much earlier in the drug development process."

Presage technology can be used to evaluate up to eight combinations of drugs or individual compounds, both investigational and approved, all without exposing patients to the toxicity of systemic dosing.

Presage is evaluating its CIVO™ platform in a first-in-human study in collaboration with the Seattle Cancer Care Alliance (SCCA) and the Fred Hutchinson Cancer Research Center, with funding support from the National Cancer Institute (NCI)<sup>1</sup>. CIVO™ also is being employed in preclinical models, including canine cancer patients and human tumor xenografts in mice.

### **About Presage Biosciences**

Presage Biosciences is an oncology company pioneering the incorporation of human efficacy data much earlier in the drug development and clinical trial processes with its patented CIVO™ arrayed microinjection platform. The CIVO platform allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient's body to assess efficacy, resistance and drug synergies in the tumor's native microenvironment. Presage partners with oncology-focused pharmaceutical companies through strategic alliances to provide in vivo data to validate novel targets, promote drug candidates to the right indications and discover effective drug combinations. Presage also is actively in-licensing cancer compounds and using CIVO™ to develop a portfolio of

promising oncology therapies to advance to the clinic. Presage is privately held and based in Seattle. For more information, visit [www.presagebio.com](http://www.presagebio.com).

# # #

**Media Contact:**

Kathryn Morris

PR On Call

845-635-9828

[kathryn@proncall.com](mailto:kathryn@proncall.com)

---

<sup>1</sup>The study is supported by a grant from the National Cancer Institute (NCI). The content of this press release is solely the responsibility of Presage and does not necessarily represent the official views of the National Institutes of Health.